Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448297 | 0.87 | ALDH1A1 (0.55) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL24754704 | 0.85 | RAB9A (0.56) | ALDH1A1POLBGAAKMT2AGPR35 | |
| SCHEMBL4422637 | 0.82 | ALDH1A1 (0.55) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2090900 | 0.82 | LPAR1 (0.55) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13382332 | 0.82 | ALDH1A1 (0.51) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30977630 | 0.82 | ALDH1A1 (0.55) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20980809 | 0.81 | GRIN2D (0.55) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL631133 | 0.78 | ALDH1A1 (0.57) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2093262 | 0.78 | ALDH1A1 (0.54) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5032627 | 0.78 | GRIN2D (0.60) | LPAR1ALDH1A1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| EP-3142649-B1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITOR EMRICASAN | CONATUS PHARMACEUTICALS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3397251-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | Conatus Pharmaceuticals, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017117478-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| CN-1283656-C | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS INC (US) | 2006-11-08 | — | — | CN | disclosed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| CN-1525978-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | 伊邓药品公司 | 2004-09-01 | — | — | CN | disclosed |
| EP-1351975-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CASP1, CASP5, CASP2 | LPAR1 3726/4885ALDH1A1 1171/4885GRIN2D 4830/4885 |
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | LPAR1 3478/4885ALDH1A1 2870/4885GRIN2D 4136/4885 |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | LPAR1 1238/4885ALDH1A1 3238/4885GRIN2D 4882/4885 |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | LPAR1 4868/4885ALDH1A1 4170/4885GRIN2D 4400/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | LPAR1 4862/4885ALDH1A1 4157/4885GRIN2D 4377/4885 |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | AOC2, AOC1, AOC3 | LPAR1 1750/4885ALDH1A1 213/4885GRIN2D 3088/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | LPAR1 3478/4885ALDH1A1 2870/4885GRIN2D 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.